Skip to main content

Table 3 RNA-seq data quality analysis results

From: Transcriptome investigation of anti‐inflammation and immuno‐regulation mechanism of taurochenodeoxycholic acid

Sample name Raw data Valid data Efficient(reads)% Q20 % Q30 % GC content%
Read Base Read Base
FCA1 54,383,990 8.16G 53,835,634 8.08G 98.99 99.58 95.01 51.50
FCA2 41,050,214 6.16G 40,649,424 6.10G 99.02 99.77 96.14 52.00
FCA3 40,700,236 6.11G 40,326,736 6.05G 99.08 99.76 95.82 51.50
AT10_1 40,741,106 6.11G 40,307,186 6.05G 98.93 99.60 95.16 51.00
AT10_2 57,742,958 8.66G 57,142,398 8.57G 98.96 99.42 92.66 50.50
AT10_3 51,520,986 7.73G 50,998,720 7.65G 98.99 99.62 93.96 50.50
AT1_1 54,593,420 8.19G 54,067,912 8.11G 99.04 99.60 93.56 51.00
AT1_2 46,452,368 6.97G 46,050,198 6.91G 99.13 99.63 93.87 51.50
AT1_3 50,198,580 7.53G 49,764,940 7.46G 99.14 99.32 91.97 51.00
AT01_1 56,340,820 8.45G 55,884,918 8.38G 99.19 99.38 92.94 52.50
AT01_2 52,741,640 7.91G 52,255,040 7.84G 99.08 99.58 94.17 51.50
AT01_3 85,115,910 12.77G 84,203,182 12.63G 98.93 99.58 94.00 50.50
  1. In the experimental design, the AA rat FLS group was represented as FCA groups in the Table 1; AA rat FLS + TCDCA high dose treatment was represented as AT10 group; AA rat FLS + TCDCA medium dose treatment was represented as AT1 group; AA rat FLS + TCDCA low dose treatment was represented as AT01 group; The numbers 1, 2, and 3 represented three sets of repeated studies